Research News

The Lymphoma Research Foundation (LRF) returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with nearly 70 LRF-affiliated scientists presenting more than 100 abstracts at this year’s conference.

Playing the long game is not a new concept for Lymphoma Research Foundation Grantee and Scientific Advisory Board (SAB) member Ari Melnick, MD, of NewYork-Presbyterian/Weill Cornell Medicine. Lymphoma research is not a field for those looking for instant gratification, but Dr. Melnick has never taken a sprinter’s approach to finding cures for lymphoma. He is more of a marathoner.

A study partially funded by the Lymphoma Research Foundation, and published in the Journal of Experimental Medicine, revealed surprising new functions for a protein called MYC.

Several oral agents have been proven active in the treatment of certain subtypes of non-Hodgkin lymphomas, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL) and Waldentröm macroglobulinemia (WM); and for…

In a study funded in part by the Lymphoma Research Foundation, researchers find the loss of specific protein amplification and transcriptional reprogramming contribute to resistance to venetoclax for patients with B-cell lymphomas Researchers from Moffitt Cancer Center and Dana-Farber Cancer…

Rituximab (Rituxan) has long been the standard of care for many lymphoma patients with relapsed follicular lymphoma (FL) and marginal zone lymphoma (MZL).  Researchers on the AUGMENT trial, a large-scale, multicenter study, sought to improve outcomes for this group of…

At the 2018 ASH Annual Meeting, Catherine Diefenbach, MD (New York University) – a past recipient of LRF’s Clinical Investigator Career Development Award – presented data from cooperative group ECOG-ACRIN’s clinical trial of a new combination of existing therapies ipilimumab…

Updated results from the JULIET trial, testing tisagenlecleucel (Kymriah) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), revealed encouraging long term results.

As novel treatments have increased survival rates and changed treatment paradigms for lymphoma, the need to better understand the side effects of these new treatments on patients has been magnified.  Some types of lymphoma are now treated with continuous pill…

  In conjunction with the Mantle Cell Lymphoma Scientific Workshop, the Lymphoma Research Foundation announced two MCL Therapeutic Studies Grants, awarded to Sandeep Dave, MD, MS of Duke University and Jianguo Tao, MD of H. Lee Moffitt Cancer Center.  As…